Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) released an announcement on February 8, 2026, detailing the composition of its Board of Directors. The Board consists of four executive directors (led by Chairman Dr. Zhang Faming), one non-executive director, and four independent non-executive directors.

According to the announcement, Dr. Zhang also chairs the Nomination Committee. Audit Committee chair responsibilities fall to Mr. Chen Qifeng, while Mr. Wong Sai Hung heads the Remuneration Committee. Other directors serve as members across these committees, including Dr. Bi Honggang, who holds memberships in both the Audit and Remuneration Committees, and Dr. Henry Qixiang Li, who is a member of the Nomination Committee.